Envirotainer and Swiss WorldCargo Use Live Monitoring of Temperature-Controlled Shipments
Envirotainer and Swiss WorldCargo have successfully completed the first commercial shipment using a new temperature-controlled air freight solution.
Envirotainer, which provides cold-chain solutions for air transportation of pharmaceuticals, announced on March 11, 2022 that the first commercial shipment using the new Releye RAP container has been successfully completed. Swiss WorldCargo, a carrier of intensive care pharmaceuticals, handled the consignment. The Releye RAP containers are temperature-controlled and allow for live monitoring during air freight, enabling insight into product condition, location, and progress of the shipment.
Three RAP units and two RAP e2 units successfully traveled from Basel, Switzerland to JFK airport in the US. The shipment was able to be monitored throughout the entire journey due to the integrated live monitoring system. In case of a critical occurrence, Envirotainer’s Control Tower service allowed a global team of operators to be ready to respond within minutes.The Releye RAP sets a new standard for temperature-controlled, large capacity solutions.
Source: Envirotainer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
